Last reviewed · How we verify
Sequential therapy 10 days
Sequential therapy is a treatment approach that involves a combination of antibiotics to treat bacterial infections.
Sequential therapy is a treatment approach that involves a combination of antibiotics to treat bacterial infections. Used for Community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis.
At a glance
| Generic name | Sequential therapy 10 days |
|---|---|
| Sponsor | Incheon St.Mary's Hospital |
| Drug class | Antibiotic |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | FDA-approved |
Mechanism of action
This approach is used to treat infections caused by resistant bacteria, where a combination of antibiotics is used to target the bacteria and prevent the development of resistance. The specific antibiotics used in sequential therapy may vary depending on the type of infection and the patient's medical history.
Approved indications
- Community-acquired pneumonia
- Acute bacterial exacerbation of chronic bronchitis
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma (PHASE3)
- CAR-T Followed by Bispecific Antibodies (PHASE2)
- Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy (PHASE1, PHASE2)
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequential therapy 10 days CI brief — competitive landscape report
- Sequential therapy 10 days updates RSS · CI watch RSS
- Incheon St.Mary's Hospital portfolio CI